Oruka Therapeutics ($ORKA) Stock Hub: Can Oruka turn lasting skin clearance into a differentiated psoriasis franchise?

03 Company history: a new immunology business inside an older listing

The operating Oruka business was formed in February 2024 around rights to antibodies developed by Paragon. Its merger with ARCA closed on August 29, 2024; post-merger, split-adjusted trading began on September 3. Headquarters are in Menlo Park. 2025 Form 10-K

That history matters when looking at long stock charts. Earlier ARCA prices, financing events and drug programs do not describe the scientific prospects of the current antibody business. A chart spanning the predecessor company can be technically continuous while economically representing a different enterprise. Reverse-split-adjusted historical prices also make unqualified comparisons with a decade-old peak misleading.

The present business model is straightforward: fund and develop proprietary biologics, validate a differentiated clinical profile and ultimately seek commercialization or a suitable partnership. There is no current product-sales base to anchor a conventional earnings multiple. The most relevant operating output is credible clinical evidence, followed by the ability to convert that evidence into an approvable and commercially competitive regimen.

04 Leadership, governance and alignment

CEO Lawrence Klein previously worked at Versant and held Chief Business Officer and Chief Operating Officer roles at CRISPR Therapeutics. CMO Joana Goncalves brings experience from Cara and the OTEZLA program at Celgene. CEO biography · CMO biography

Todd Edwards, appointed Chief Commercial Officer in August, previously led commercial work at Arcutis and held immunology roles at Incyte and UCB. That background is relevant to eventual access and launch planning; it is not evidence that a launch date has been established. Commercial leadership biography · Appointment announcement

The April proxy identifies Samarth Kulkarni as board chair and a staggered, three-class board. Other directors include Kristine Ball, Carl Dambkowski, Peter Harwin and Chris Martin. 2026 proxy statement

Governance deserves attention because Fairmount, Paragon and Oruka have overlapping economic relationships. Fairmount has board representation and interests in the licensor. Related-party arrangements can bring specialist expertise and access to assets, but investors should examine licensing terms and capital allocation independently. The appropriate management scorecard is practical: truthful schedule updates, transparent denominators, sensible Phase 3 design and disciplined spending.

05 What Oruka is trying to improve

Oruka’s engineering strategy combines target binding, longer antibody circulation and formulation work. The goal is to maintain useful exposure for longer while preserving efficacy, tolerability and manufacturability. ORKA-001 targets IL-23p19; ORKA-002 targets IL-17A/F. These are established inflammatory pathways, but each investigational molecule must establish its own benefit-risk profile. Company pipeline and engineering overview

A long pharmacokinetic half-life describes how slowly drug levels fall. It does not automatically establish how long a patient remains clear, how quickly symptoms return, or which minimum exposure is required. Clinical durability must be measured in the intended population. The distinction is especially important when extrapolating from healthy-volunteer blood concentrations to chronic inflammatory disease.

PASI 100 means complete improvement in the Psoriasis Area and Severity Index relative to baseline; PASI 90 means at least 90% improvement. These are useful efficacy endpoints, but investors should also consider physician assessments, patient-reported burden, rescue treatment, discontinuations and missing-data handling. A compelling curve can become less compelling if maintenance requires extensive rescue dosing or if favorable results depend on selecting only the best initial responders.

06 Pipeline map: separate current programs from optionality

September pipeline deck · Annual filing

The pipeline should not be counted as five independent, equally mature assets. Two programs currently carry most of the near-term evidence burden. The earlier programs are options on future development, with additional formulation, safety, trial-design and funding requirements. Combining antibodies also increases complexity: success of each individual component does not establish that a combination improves outcomes enough to justify its cost or exposure.

07 EVERLAST-A: what the completed results establish

EVERLAST-A enrolled 84 patients, randomized 3:1. The active arm received 600 mg at Weeks 0 and 4. At Week 16, PASI 100 was achieved by 40/63 patients (63.5%); adverse-event rates were 51% with active treatment and 57% with placebo. April 27 data release

On September 23, Oruka reported Week 28 PASI 100 of 45/63 (71.4%), PASI 90 of 55/63 (87.3%), and IGA 0/1 of 53/63 (84.1%). No further initial-arm dosing occurred after Week 4. Two serious events in the Week 16–28 interval were reported as unrelated to treatment. These are company-reported results, not a guarantee of later safety. Week 28 update

The result supports a real question worth testing: can clearance persist and deepen over a long interval without repeated induction? The study remains small, and the later period includes crossover from placebo. Consequently, the Week 28 response should not be read as a new, fully placebo-controlled comparison against every alternative therapy.

December’s 52-week analysis is especially important because durability claims become progressively more demanding as follow-up lengthens. The useful disclosure will separate patients who received maintenance from those observed without additional treatment, report retreatment and discontinuation, and retain clear denominators. Annual dosing is still a proposed product feature. A year of observation and a validated once-yearly regimen are not interchangeable claims.

08 EVERLAST-B: reproducibility and dose selection

The September deck identifies EVERLAST-B as NCT07290569, with 187 participants, four randomized groups and PASI 100 at Week 16 as the primary endpoint. Active induction regimens include 600 mg and 300 mg at Weeks 0/4, plus a deliberately low 37.5 mg dose; the fourth group is placebo. Trial design, slide 18 · Trial registry

This readout carries more weight than an enrollment announcement. It tests whether the initial clinical signal survives a broader dose-ranging experiment and whether a practical dose can support the next development stage. A clean dose-response pattern would help interpretation. A flat result is not automatically bad if several doses are on the response plateau, but inconsistent groups or a unexpectedly weak high-dose arm would require explanation.

The low-dose arm is intentionally included for dose ranging, so it should not be judged by the same commercial expectations as the intended therapeutic regimens. Conversely, highlighting only the best-performing group while ignoring the full randomized dataset would make the evidence less persuasive. Investors should check placebo response, baseline balance, confidence intervals and sensitivity analyses, rather than compare headline percentages alone.

Management expects the results in Q4 2026 and intends them to support a Phase 3 start in the first half of 2027. A successful Phase 2b study would improve the development case; it would not complete the evidence required for approval.

09 ORKA-002: another mechanism, another proof requirement

The initial ORKA-002 study involved 24 healthy adults across three ascending-dose cohorts. January data indicated a 75–80 day half-life and no serious or severe treatment-emergent events in the interim report. The twice-yearly psoriasis maintenance concept was supported by modeling, not demonstrated patient efficacy at that point. January Phase 1 release

ORCA-SURGE is designed around roughly 160 patients, three active dose groups and placebo, with Week 16 PASI 100 as its primary endpoint. The active induction doses are 40, 160 and 320 mg at Weeks 0 and 4. The current readout window is Q1 2027. Study design · Updated timing · NCT07474792

This is the most useful diversification in the near-term calendar: an efficacy test of another molecule against a different inflammatory target. Nevertheless, it shares commercial exposure to psoriasis and some organizational risks with ORKA-001. It is not an independent hedge against a sector selloff, manufacturing problems or a reassessment of convenience-based differentiation.

For interpretation, look beyond whether the primary endpoint is met. The questions are whether clearance is clinically competitive, which dose delivers it, how tolerability evolves with repeated dosing, and whether pharmacokinetics support the proposed maintenance interval in patients. Healthy-volunteer tolerability cannot rule out uncommon events or disease-specific risks in larger studies.

10 HS, TL1A and the next layer of optionality

ORCA-SPLASH studies ORKA-002 in hidradenitis suppurativa. The planned approximately 160-patient trial compares 320 mg against placebo at Weeks 0/4/8/12, with HiSCR75 at Week 16 as the primary endpoint and an open-label maintenance period. No precise readout window is counted in this six-month catalyst screen. August development update

HS is not simply psoriasis with another label. Disease burden, lesion assessment, patient variability and the clinical bar differ. A positive psoriasis result would validate aspects of the molecule but would not settle HS efficacy. Investors should resist adding the full addressable markets of both indications before each has clinical support.

ORKA-004’s planned clinical entry is a development milestone, below an efficacy readout in immediate evidentiary weight. The TL1A combination strategy offers a route to deeper control or broader indications, but currently adds uncertainty about patient selection, contribution of each component and regulatory expectations. No probability-adjusted dollar value is assigned here.

This distinction keeps the catalyst calendar honest. Starting a trial can demonstrate execution. A patient-outcome readout can change the estimated probability of a successful product. They can both matter, but should not be treated as equivalent binary events.

11 Catalyst calendar: remaining events and their quality

Latest ORKA-001 timing · Program schedule · September confirmation

The company has not committed to exact announcement days for the three main readouts. EVERLAST-B and the December durability update could occur close together or even be presented together; no separation is assumed within Q4. The ORCA-SURGE window is in the following quarter, satisfying the key distinction between important events at different times. September 23 Week 28 results are completed and excluded from the upcoming list.

Quarter-end dates in a calendar must be labeled as window boundaries, never disguised as scheduled data-release days. A schedule extension should trigger a factual update, not an automatic clinical-failure conclusion.

12 Cash, spending and the development budget

Q2 financial release · Q1 release · Cash-flow statement and subsequent events

The cash step-up primarily reflects equity financing. It is not evidence of an operating business generating cash. Likewise, purchases of marketable securities are cash-flow movements between financial assets; counting them as clinical burn would greatly overstate operating consumption.

Management says its resources fund operations through the anticipated ORKA-001 BLA filing and continued ORKA-002 development. That is a plan-dependent runway statement, not a fixed calendar guarantee. Phase 3 expansion, combination studies, manufacturing commitments and commercial preparation can materially increase spending. Extrapolating the first-half burn into a decade of runway would be misleading.

The balance sheet creates strategic flexibility: trials can be planned around scientific needs rather than immediate refinancing. The next financial checks are actual quarterly operating cash use, the cost of the registrational plan and the amount of equity issued between reporting dates.

13 Capital structure and dilution: ordinary shares are only the start

The SEC cover reports 66,209,699 common shares at July 31. Add 7,874,739 common equivalents from remaining preferred stock after July’s conversion and 5,706,188 June pre-funded warrants: approximately 79.79 million. This mixes disclosed dates and assumes no subsequent warrant changes; it is not a current fully diluted denominator. Q2 filing, cover and Notes 7/13

Other outstanding instruments include options, employee warrants, Paruka warrants and restricted stock units. The August prospectus separately lists those categories. Awards require attention to exercise prices, vesting and potential proceeds; simply adding authorized but unissued shares is not a sensible diluted-value calculation. Prospectus capital exclusions

The latest prospectus covers up to $500 million of ATM sales. The older $35.3 million remaining-capacity figure after July is therefore not the current facility description. Actual subsequent sales have not been established here. Capacity authorizes potential issuance; it is not cash already received.

At an unchanged hypothetical $84.46 sale price, $500 million would correspond to approximately 5.92 million new shares before fees. This is arithmetic illustrating possible share supply, not a forecast that Oruka will sell that amount or at that price. Strong clinical news can improve financing terms while still leading management to raise additional capital. Shareholders should evaluate both the scientific benefit and their ownership percentage after financing.

14 Institutions and insiders: useful evidence with dated boundaries

Counts were cross-checked across StockScreener and ByteSize Finance. They are delayed vendor aggregations, not a verified September ownership register. Percentages of “tracked 13F value” are not percentages of Oruka’s shares.

Two primary filings add important context. Fairmount converted preferred stock and sold 3,553,410 common shares on July 1 at $84.43; conversion itself did not create new cash for Oruka. On September 15, CEO Klein sold 2,452 shares at $95.71 through an automatic tax sell-to-cover procedure, retaining 923,128 directly reported common shares. Fairmount Form 4 · CEO Form 4

An institutional name on the register is not an endorsement of today’s entry price. Managers may hedge, rebalance or hold different instruments, and reported long positions do not reveal the complete trade. Tax withholding sales should not be described as discretionary bearish calls. Conversely, specialist ownership should not be used to dismiss adverse clinical evidence.

15 Competition: the bar is already high

SKYRIZI dosing · TREMFYA dosing · BIMZELX dosing and safety · ICOTYDE approval

These regimens are context, not treatment recommendations or a claim of comparative efficacy. Different study populations, follow-up periods, endpoints and missing-data rules make cross-trial rankings uncertain. ORKA-001 has not established head-to-head superiority over these products.

Commercial differentiation can come from several sources: clearance, speed, durability, ease of administration, safety, adherence and cost. An attractive dosing interval may lose impact if induction is burdensome, payers prefer discounted alternatives or patients are reluctant to switch a working therapy. Oruka must eventually compete against the complete incumbent offering, including evidence, access programs and physician confidence, rather than against a single dosing-frequency statistic.

16 Rights, patents and manufacturing economics

The annual filing describes exclusive Paragon licenses for ORKA-001 and ORKA-002. It indicates 2045 expiry for certain ORKA-001 patent rights and, if issued, relevant ORKA-002 rights, before applicable adjustments or extensions. These statements do not establish a universal 2045 exclusivity guarantee. Intellectual-property disclosures

The Paragon agreements carry development/regulatory milestones and low-single-digit royalties. The company also licensed Halozyme Hypercon technology for formulation work; the Q1 update describes its potential to improve the eventual product profile. License terms · Formulation collaboration

Patent duration, patent strength and commercial exclusivity are different questions. An issued claim may have limited scope; an application may not issue as hoped. Formulation changes can improve convenience but may require additional comparability work, manufacturing development and regulatory evidence. They can also add royalties or other economics that reduce the cash retained from future sales.

The analytical issue is whether an infrequently administered antibody can be produced consistently, delivered at a practical volume and supported by a reliable supply chain. Larger doses are not automatically a commercial disadvantage, but concentration, viscosity, device design and manufacturing yield become relevant. No commercial gross-margin assumption is presented as established fact before those elements are defined.

17 Valuation framework: strong science is not the same as a cheap stock

At the September 25 close, ordinary equity value is about $5.59 billion. A simple subtraction of June cash and securities produces approximately $4.47 billion before subsequent cash movements and instrument adjustments, consistent with a public vendor’s reported enterprise-value context. Market snapshot

Using the broader 79.79 million common-equivalent base at that same price gives approximately $6.74 billion of equity value. Subtracting June resources gives roughly $5.61 billion before July proceeds, later burn, other awards, leases and future obligations. These are deliberately labeled reference calculations, not a completed current enterprise-value bridge. They show why the capital denominator materially changes the apparent cost of the pipeline.

A defensible valuation would model each indication separately: probability of technical and regulatory success, launch timing, eligible patients, uptake, net realized price, royalty burden, development cost and future financing. It would then discount future cash flows and divide by a consistent diluted share base. An unsupported peak-sales multiple or a broker target cannot substitute for those assumptions.

No target price or implied return is assigned here. The observable valuation hurdle is already substantial. Good data must either increase the probability of a valuable franchise, expand its plausible economics or reduce development risk enough to justify that hurdle. The absence of a target is a boundary on the analysis, not a suggestion that any price is acceptable.

Analyst coverage: the underlying dated brokerage notes have not been independently verified for this update, so this hub does not reproduce a target-price table or treat a vendor consensus as established fair value.

18 Short interest, liquidity and the difference between a debate and a squeeze

September 15 short interest was 7,623,327 shares. Finviz displays roughly 13% of estimated float; MarketBeat displays roughly 15%. The underlying short count agrees while float definitions differ. Finviz’s observed average volume was approximately 1.08 million shares. Dated short history · Trading snapshot

This is meaningful positioning, but it is not an exceptionally tiny-float setup. Shorts may cover after a strong result, add after a valuation disappointment, or remain hedged against other exposures. A percentage alone reveals neither borrow pressure nor how much buying would be forced. Current borrow fees, utilization, option positioning and dealer exposure were not verified and are not estimated.

The September 25 close sat below the recent annual high despite constructive clinical messaging. The important market question is therefore the expectation gap: how much durability and commercial success was already assumed before the release? A positive study can coincide with a negative stock reaction when expectations were higher.

No numerical Stocktwits sentiment score is asserted. Reader discussion can help identify contested questions, but message volume, bullish tags and social attention are not substitutes for trial evidence. A sound monitoring process compares the incoming data with the pre-announced clinical questions, rather than rewriting the thesis after observing the first price reaction.

19 Scenarios, disconfirmers and the next evidence to demand

These are qualitative scenarios, not assigned probabilities or price forecasts. They are designed to prevent an all-or-nothing reading of a complex dataset. A program can remain viable while the stock thesis weakens, and a disappointing secondary measure can coexist with a useful overall product.

Thesis disconfirmers: loss of a meaningful dosing advantage; inconsistent efficacy in intended therapeutic arms; material treatment-related safety signals; poor durability once rescue and missing data are included; manufacturing or formulation requirements that complicate the product; and a development plan whose cost or timing exceeds the value being added.

Evidence that would improve confidence: complete randomized tables, denominators and confidence intervals; outcomes by maintenance assignment; retreatment rates; a transparent Phase 3 plan; safety across longer exposure; and a reconciled quarter-end capital structure. These are observable checks, not demands for perfect results.

Overall, Oruka offers a coherent clinical thesis and a dense evidence calendar. It also carries a substantial expectation burden. The next investment-relevant step is to assess each readout against the product characteristics it must prove, while updating cash, share count and competitive context. This hub is educational research, not a buy/sell recommendation or a claim that a strong return is likely.

20 Sources, cut-off and evidence quality

Research cut-off: September 27, 2026. Regular-session price: September 25. Financial balance sheet: June 30, with separately identified subsequent events. Short-interest settlement date: September 15. Management guidance is forward-looking and can change. Clinical evidence confidence is high for what the company disclosed; comparative superiority, approval, commercialization and future returns remain unproven.

Primary clinical sources: September Week 28 release; April Week 16 release; ORKA-002 Phase 1 report; September corporate deck.

Primary corporate and financial sources: Q2 Form 10-Q; 2025 Form 10-K; Q2 earnings release; Q1 earnings release; August 27 ATM prospectus; 2026 proxy; Fairmount Form 4; CEO Form 4.

Source conflicts resolved here: SEC July ordinary shares take precedence over vendors still showing June counts; latest ATM terms replace the smaller July remainder; the September clinical update supersedes older data windows; vendor float percentages are shown as a range. Institutional tables remain delayed third-party summaries and should not be presented as live beneficial ownership. The general pipeline webpage still shows an older stage for ORKA-002; current releases and the September deck establish the Phase 2 status used here.